After 37 years of pioneering health journalism, community engagement, and empowerment through information, we have now ceased operations.
This website will be accessible until September 2025, with all the information being up to date as of July 2024.
If you are a supplier, or another partner you can contact our legacy email address as aidsmap@outlook.com with any queries.
We extend our heartfelt thanks to everyone who supported our vision for a world where HIV is no longer a threat to health or happiness. Together we have made a difference.
CROI 2023: Lenacapavir and two broadly neutralising antibodies for treatment
At CROI 2023, Professor Joseph Eron from University of North Carolina spoke to NAM's Roger Pebody about lenacapavir and two broadly neutralising antibodies for treatment.
